Anti?heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID?19

The aim of this study is to evaluate the blood level anti-heart antibodies (AHA) and its correlation with clinical outcomes in patients severe moderate coronavirus disease 2019 (COVID-19). included 34 (23 males; mean age 60.2 ± 16.6 years) COVID-19 pneumonia. Besides standard medical examination, AHA levels were observed, including antinuclear antibodies, antiendothelial cell anti-cardiomyocyte (AbC), anti-smooth muscle (ASMA), cardiac conducting tissue antibodies. Median hospital length stay was 14 [13; 18] days. increased 25 (73.5%) patients. Significant (p < 0.05) cardiovascular manifestations (r = 0.459) found. AbC correlated pneumonia severity 0.472), respiratory failure 0.387), need for invasive ventilation 0.469), chest pain 0.374), low QRS voltage 0.415), C-reactive protein 0.360) lactate dehydrogenase 0.360). ASMA found correlate atrial fibrillation 0.414, p 0.05). Antinuclear pericardial effusion 0.721 r 0.745, respectively, lethality rate 8.8%. significantly 0.363 0.426, prognostically important. can be considered as part systemic immune inflammatory response COVID-19. Its possible role heart requires further investigation.